Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
INO Stock Chart & Stats
$2.12
-$0.22(-9.65%)
At close: 4:00 PM EST
$2.12
-$0.22(-9.65%)
Day’s Range― - ―
52-Week Range$1.30 - $5.60
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.13M
Market Cap
$112.66M
Enterprise Value$42.13M
Total Cash (Recent Filing)$47.55M
Total Debt (Recent Filing)$10.66M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Mar 03, 2026EPS Estimate
-0.42Last Dividend Ex-Date
Sep 28, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding53,142,662
10 Day Avg. Volume1,525,802
30 Day Avg. Volume1,132,203
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.73
Price to Sales (P/S)228.26
P/FCF Ratio-0.48
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue231.04
Enterprise Value/Gross Profit-20.05
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.96Price Target Upside228.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyLong-term efficacy data from a retrospective study demonstrate that INO-3107 provided significant clinical benefit to RRP patients, as measured by reduction in surgery.
Market EntryINO-3107 may be the second RRP treatment to enter the market; however, it does not require surgical removal of papilloma during the treatment.
Regulatory AdvancementsINO-3107 has been granted Orphan Drug and Breakthrough Therapy designations.
Bears Say
CompetitionA potential competitor for the treatment of recurrent respiratory papillomatosis (RRP) has a PDUFA date of August 27, 2025.
Financial NeedsThe company may need to raise additional capital within the next 12 months.
Regulatory RisksRisks include failure of INO-3107 in clinical trials, failure to secure regulatory approval, and failure to achieve commercial success due to market size, penetration rate, and/or competition.
Inovio Pharmaceuticals News
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.30 and its highest was $5.60 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $112.66M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 112 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.422 by -$0.448.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals pays a Monthly dividend of $0.069 which represents an annual dividend yield of N/A. See more information on Inovio Pharmaceuticals dividends here
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.42.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 53,142,662 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.422. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.96 (228.30% Upside)
$6.96 (228.30% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-61.59%
12-Months-Change
Fundamentals
Return on Equity
-140.12%
Trailing 12-Months
Asset Growth
-49.00%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals (INO) is a biotechnology company focused on developing innovative DNA-based immunotherapies and vaccines for the treatment of cancer and infectious diseases. The company specializes in its proprietary platform technology that delivers therapeutic DNA plasmids into the body, harnessing the immune system to generate a targeted response. Inovio's core products include its investigational therapies for various cancers and its work on vaccines against infectious diseases, including COVID-19.
INO Company Deck
INO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant milestones such as the BLA submission for INO-3107 and cost management achievements. However, challenges persist with increased net loss and reduced cash reserves. Progress in clinical trials and pipeline advancements are promising, but financial constraints pose concerns.View all INO earnings summariesINO Stock 12 Month Forecast
Average Price Target
$6.96
▲(228.30% Upside)
Technical Analysis
Agenus
―
Oncolytics Biotech
―
Oncolytics Biotech
―
Atossa Therapeutics
―
Anixa Biosciences
―
Instil Bio
―
Ownership Overview
0.54% Insiders
4.85% Mutual Funds
0.09% Other Institutional Investors
90.64% Public Companies and
Individual Investors